
Achim Rittmeyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4923903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, The, 2017, 389, 255-265.	13.7	3,872
2	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, The, 2016, 387, 1837-1846.	13.7	2,390
3	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	10.7	1,133
4	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine, 2018, 24, 1441-1448.	30.7	936
5	Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089). Journal of Clinical Oncology, 2013, 31, 3004-3011.	1.6	301
6	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1156-1170.	1.1	195
7	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research, 2019, 25, 64-72.	7.0	159
8	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer, 2019, 128, 105-112.	2.0	126
9	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. Journal of Thoracic Oncology, 2021, 16, 140-150.	1.1	95
10	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 2018, 13, 1906-1918.	1.1	88
11	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose EscalationÂStudy. Journal of Thoracic Oncology, 2016, 11, 2208-2217.	1.1	66
12	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 441-449.e4.	2.6	65
13	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	2.0	53
14	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research, 2018, 24, 3292-3298.	7.0	41
15	Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy, 2019, 11, 1445-1461.	2.0	37
16	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 43-49.	2.6	31
17	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). Journal of Thoracic Oncology, 2013, 8, 1409-1416.	1.1	24
18	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clinical Medicine Insights: Oncology, 2020, 14, 117955492095135.	1.3	24

#	Article	IF	CITATIONS
19	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	2.8	23
20	Smoking Cessation in Lung Cancer. Deutsches Ärzteblatt International, 2013, 110, 719-24.	0.9	23
21	Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Translational Lung Cancer Research, 2020, 9, 603-616.	2.8	21
22	Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial. OncoTargets and Therapy, 2017, Volume 10, 1081-1089.	2.0	18
23	Treatment of limited disease small cell lung cancer: the multidisciplinary team. European Respiratory Journal, 2017, 50, 1700422.	6.7	17
24	Multidisciplinary treatment of lung cancer in older patients: A review. Journal of Geriatric Oncology, 2019, 10, 405-410.	1.0	17
25	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR) Journal of Clinical Oncology, 2016, 34, 9028-9028.	1.6	16
26	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study Journal of Clinical Oncology, 2017, 35, 9001-9001.	1.6	16
27	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR Journal of Clinical Oncology, 2016, 34, 9032-9032.	1.6	14
28	Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2017, 17, 781-789.	3.1	13
29	Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
30	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer, 2022, 23, 21-33.	2.6	12
31	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Lung Cancer, 2021, 160, 17-27.	2.0	10
32	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Immunotherapy, 2019, 11, 769-782.	2.0	9
33	Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. Cancers, 2015, 7, 950-962.	3.7	4
34	Update on recent key publications in lung oncology: picking up speed. European Respiratory Review, 2021, 30, 200300.	7.1	1
35	Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. BMC Pulmonary Medicine, 2022, 22, .	2.0	1
36	Reply to B.M. Strebel. Journal of Clinical Oncology, 2014, 32, 479-480.	1.6	0